	US 11,701,416 B2
	Multivalent pneumococcal vaccines
Richard Malley, Beverly, MA (US); Yingjie Lu, West Roxbury, MA (US); Fan Zhang, West Roxbury, MA (US); Teresa J. Broering, Brookline, MA (US); Shite Sebastian, Shrewsbury, MA (US); Velupillai Puvanesarajah, Chapel Hill, NC (US); and George R. Siber, New York, NY (US)
Assigned to Affinivax, Inc., Cambridge, MA (US)
Filed by Affinivax, Inc., Cambridge, MA (US)
Filed on Apr. 22, 2021, as Appl. No. 17/237,168.
Application 17/237,168 is a division of application No. 16/569,579, filed on Sep. 12, 2019, granted, now 11,013,793.
Claims priority of provisional application 62/730,471, filed on Sep. 12, 2018.
Prior Publication US 2021/0346487 A1, Nov. 11, 2021
Int. Cl. A61K 39/09 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/092 (2013.01) [A61K 2039/55505 (2013.01); A61K 2039/62 (2013.01); A61K 2039/70 (2013.01)]

38 Claims

1. A method of immunizing a subject against Streptococcus pneumoniae infection and/or colonization comprising administering to the subject an immunologically effective amount of a multivalent vaccine comprising fifteen or more species of immunogenic complexes, wherein each species of the immunogenic complexes comprises:

(a) a biotinylated polysaccharide antigen comprising biotin and a polysaccharide antigen from a distinct Streptococcus pneumoniae serotype; and

(b) a fusion protein comprising:

(i) a biotin-binding moiety; and

(ii) at least one polypeptide antigen comprising;

a first polypeptide antigen comprising an SP1500 polypeptide or an antigenic fragment thereof; and

a second polypeptide antigen comprising an SP0785 polypeptide or an antigenic fragment thereof;

wherein the fusion protein comprises an amino acid sequence at least 90% identical to SEQ ID NO:6; and

wherein in each species of the immunogenic complexes, the biotinylated polysaccharide antigen is non-covalently associated with the biotin-binding moiety of the fusion protein.